{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T15:37:47Z","timestamp":1791041867071,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1038\/s41574-024-01074-9","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T23:30:28Z","timestamp":1736119828000},"page":"314-324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5105-8427","authenticated-orcid":false,"given":"Ravi","family":"Savarirayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1242-5626","authenticated-orcid":false,"given":"Julie","family":"Hoover-Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6517-8825","authenticated-orcid":false,"given":"Keiichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Backeljauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2839-9856","authenticated-orcid":false,"given":"Val\u00e9rie","family":"Cormier-Daire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6540-4028","authenticated-orcid":false,"given":"Kristen","family":"DeAndrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penny","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melita","family":"Irving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Llerena Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7183-5238","authenticated-orcid":false,"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Menzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5113-8657","authenticated-orcid":false,"given":"Klaus","family":"Mohnike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana Noval","family":"Iruretagoyena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein Otto","family":"Fredwall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"1074_CR1","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1093\/hmg\/ddu004","volume":"23","author":"F Di Rocco","year":"2014","unstructured":"Di Rocco, F. et al. FGFR3 mutation causes abnormal membranous ossification in achondroplasia. Hum. Mol. Genet. 23, 2914\u20132925 (2014).","journal-title":"Hum. Mol. Genet."},{"key":"1074_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/371252a0","volume":"371","author":"F Rousseau","year":"1994","unstructured":"Rousseau, F. et al. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia. Nature 371, 252\u2013254 (1994).","journal-title":"Nature"},{"key":"1074_CR3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/0092-8674(94)90302-6","volume":"78","author":"R Shiang","year":"1994","unstructured":"Shiang, R. et al. Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia. Cell 78, 335\u2013342 (1994).","journal-title":"Cell"},{"key":"1074_CR4","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/ajmg.a.61289","volume":"179","author":"A Coi","year":"2019","unstructured":"Coi, A. et al. Epidemiology of achondroplasia: a population-based study in Europe. Am. J. Med. Genet. A 179, 1791\u20131798 (2019).","journal-title":"Am. J. Med. Genet. A"},{"key":"1074_CR5","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1002\/ajmg.a.61787","volume":"182","author":"PK Foreman","year":"2020","unstructured":"Foreman, P. K. et al. Birth prevalence of achondroplasia: a systematic literature review and meta-analysis. Am. J. Med. Genet. A 182, 2297\u20132316 (2020).","journal-title":"Am. J. Med. Genet. A"},{"key":"1074_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13023-018-0972-6","volume":"14","author":"RM Pauli","year":"2019","unstructured":"Pauli, R. M. Achondroplasia: a comprehensive clinical review. Orphanet J. Rare Dis. 14, 1 (2019).","journal-title":"Orphanet J. Rare Dis."},{"key":"1074_CR7","doi-asserted-by":"publisher","first-page":"6166","DOI":"10.1080\/09638288.2021.1963853","volume":"44","author":"C Constantinides","year":"2022","unstructured":"Constantinides, C., Landis, S. H., Jarrett, J., Quinn, J. & Ireland, P. J. Quality of life, physical functioning, and psychosocial function among patients with achondroplasia: a targeted literature review. Disabil. Rehabil. 44, 6166\u20136178 (2022).","journal-title":"Disabil. Rehabil."},{"key":"1074_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02652-2","volume":"18","author":"M Maghnie","year":"2023","unstructured":"Maghnie, M. et al. Lifetime impact of achondroplasia study in Europe (LIAISE): findings from a multinational observational study. Orphanet J. Rare Dis. 18, 56 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"1074_CR9","doi-asserted-by":"publisher","first-page":"S127","DOI":"10.1016\/S1096-7192(21)00280-8","volume":"132","author":"M Maghnie","year":"2021","unstructured":"Maghnie, M. et al. Health-related quality of life (HRQoL) in achondroplasia: findings from a multinational, observational study. Mol. Genet. Metab. 132, S127\u2013S128 (2021).","journal-title":"Mol. Genet. Metab."},{"key":"1074_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/ajmg.a.61903","volume":"185","author":"KM Pfeiffer","year":"2021","unstructured":"Pfeiffer, K. M. et al. Assessing physical symptoms, daily functioning, and well-being in children with achondroplasia. Am. J. Med. Genet. A 185, 33\u201345 (2021).","journal-title":"Am. J. Med. Genet. A"},{"key":"1074_CR11","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/ajmg.a.62534","volume":"188","author":"KM Pfeiffer","year":"2022","unstructured":"Pfeiffer, K. M. et al. Functioning and well-being in older children and adolescents with achondroplasia: a qualitative study. Am. J. Med. Genet. A 188, 454\u2013462 (2022).","journal-title":"Am. J. Med. Genet. A"},{"key":"1074_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/mgg3.1891","volume":"10","author":"R Shediac","year":"2022","unstructured":"Shediac, R. et al. Experiences of children and adolescents living with achondroplasia and their caregivers. Mol. Genet. Genom. Med. 10, e1891 (2022).","journal-title":"Mol. Genet. Genom. Med."},{"key":"1074_CR13","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1007\/s12325-023-02549-3","volume":"40","author":"MC Murton","year":"2023","unstructured":"Murton, M. C. et al. Burden and treatment of achondroplasia: a systematic literature review. Adv. Ther. 40, 3639\u20133680 (2023).","journal-title":"Adv. Ther."},{"key":"1074_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2021.101392","volume":"57\u201358","author":"P Backeljauw","year":"2021","unstructured":"Backeljauw, P. et al. Impact of short stature on quality of life: a systematic literature review. Growth Horm. IGF Res. 57\u201358, 101392 (2021).","journal-title":"Growth Horm. IGF Res."},{"key":"1074_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.115872","volume":"146","author":"J Hoover-Fong","year":"2021","unstructured":"Hoover-Fong, J. et al. Lifetime impact of achondroplasia: current evidence and perspectives on the natural history. Bone 146, 115872 (2021).","journal-title":"Bone"},{"key":"1074_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/dvdy.24479","volume":"246","author":"DM Ornitz","year":"2017","unstructured":"Ornitz, D. M. & Legeai-Mfrallet, L. Achondroplasia: development, pathogenesis, and therapy. Dev. Dyn. 246, 291\u2013309 (2017).","journal-title":"Dev. Dyn."},{"key":"1074_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/cge.13542","volume":"97","author":"SO Fredwall","year":"2020","unstructured":"Fredwall, S. O. et al. Current knowledge of medical complications in adults with achondroplasia: a scoping review. Clin. Genet. 97, 179\u2013197 (2020).","journal-title":"Clin. Genet."},{"key":"1074_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2023.104850","volume":"66","author":"R Onesimo","year":"2023","unstructured":"Onesimo, R. et al. How pain affect real life of children and adults with achondroplasia: a systematic review. Eur. J. Med. Genet. 66, 104850 (2023).","journal-title":"Eur. J. Med. Genet."},{"key":"1074_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s10195-019-0541-3","volume":"21","author":"GA Hosny","year":"2020","unstructured":"Hosny, G. A. Limb lengthening history, evolution, complications and current concepts. J. Orthop. Traumatol. 21, 3 (2020).","journal-title":"J. Orthop. Traumatol."},{"key":"1074_CR20","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00431-017-2923-y","volume":"176","author":"D Harada","year":"2017","unstructured":"Harada, D. et al. Final adult height in long-term growth hormone-treated achondroplasia patients. Eur. J. Pediatr. 176, 873\u2013879 (2017).","journal-title":"Eur. J. Pediatr."},{"key":"1074_CR21","doi-asserted-by":"publisher","first-page":"982","DOI":"10.3109\/09638288.2011.631677","volume":"34","author":"F Schiedel","year":"2012","unstructured":"Schiedel, F. & R\u00f6dl, R. Lower limb lengthening in patients with disproportionate short stature with achondroplasia: a systematic review of the last 20 years. Disabil. Rehabil. 34, 982\u2013987 (2012).","journal-title":"Disabil. Rehabil."},{"key":"1074_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jor.2015.01.001","volume":"12","author":"J Donaldson","year":"2015","unstructured":"Donaldson, J., Aftab, S. & Bradish, C. Achondroplasia and limb lengthening: results in a UK cohort and review of the literature. J. Orthop. 12, 31\u201334 (2015).","journal-title":"J. Orthop."},{"key":"1074_CR23","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1080\/08035250510039982","volume":"94","author":"NT Hertel","year":"2005","unstructured":"Hertel, N. T. et al. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial. Acta Paediatr. 94, 1402\u20131410 (2005).","journal-title":"Acta Paediatr."},{"key":"1074_CR24","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00774-003-0425-7","volume":"21","author":"H Kanazawa","year":"2003","unstructured":"Kanazawa, H. et al. Efficacy of growth hormone therapy for patients with skeletal dysplasia. J. Bone Min. Metab. 21, 307\u2013310 (2003).","journal-title":"J. Bone Min. Metab."},{"key":"1074_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000446958","volume":"86","author":"M Miccoli","year":"2016","unstructured":"Miccoli, M., Bertelloni, S. & Massart, F. Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis. Horm. Res. Paediatr. 86, 27\u201334 (2016).","journal-title":"Horm. Res. Paediatr."},{"key":"1074_CR26","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/S0030-5898(20)31692-8","volume":"22","author":"M Saleh","year":"1991","unstructured":"Saleh, M. & Burton, M. Leg lengthening: patient selection and management in achondroplasia. Orthop. Clin. North. Am. 22, 589\u2013599 (1991).","journal-title":"Orthop. Clin. North. Am."},{"key":"1074_CR27","first-page":"53","volume":"53","author":"Y Seino","year":"2000","unstructured":"Seino, Y. et al. Growth hormone therapy in achondroplasia. Horm. Res. 53, 53\u201356 (2000).","journal-title":"Horm. Res."},{"key":"1074_CR28","doi-asserted-by":"crossref","unstructured":"Vilarrubias, J. M., Ginebreda, I. & Jimeno, E. Lengthening of the lower limbs and correction of lumbar hyperlordosis in achondroplasia. Clin. Orthop. Relat. Res. 143\u2013149 (1990).","DOI":"10.1097\/00003086-199001000-00017"},{"key":"1074_CR29","unstructured":"US Food and Drug Administration. FDA approves first drug to improve growth in children with most common form of dwarfism. FDA www.fda.gov\/news-events\/press-announcements\/fda-approves-first-drug-improve-growth-children-most-common-form-dwarfism (2021)."},{"key":"1074_CR30","unstructured":"European Medicines Agency. Voxzogo. EMA www.ema.europa.eu\/en\/medicines\/human\/EPAR\/voxzogo (2021)."},{"issue":"1 Suppl.","key":"1074_CR31","first-page":"56","volume":"1","author":"J Hoover-Fong","year":"2023","unstructured":"Hoover-Fong, J. et al. Persistence of growth promoting effects in children with achondroplasia over seven years: update from phase II extension study with vosoritide [abstract P194]. GIM Open 1(1 Suppl.), 56 (2023).","journal-title":"GIM Open"},{"key":"1074_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1358\/dot.2022.58.9.3422313","volume":"58","author":"DM Paton","year":"2022","unstructured":"Paton, D. M. Efficacy of vosoritide in the treatment of achondroplasia. Drugs Today 58, 451\u2013456 (2022).","journal-title":"Drugs Today"},{"key":"1074_CR33","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1056\/NEJMoa1813446","volume":"381","author":"R Savarirayan","year":"2019","unstructured":"Savarirayan, R. et al. C-type natriuretic peptide analogue therapy in children with achondroplasia. N. Engl. J. Med. 381, 25\u201335 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1074_CR34","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1016\/j.gim.2022.08.015","volume":"24","author":"R Savarirayan","year":"2022","unstructured":"Savarirayan, R. et al. Growth parameters in children with achondroplasia: a 7-year, prospective, multinational, observational study. Genet. Med. 24, 2444\u20132452 (2022).","journal-title":"Genet. Med."},{"key":"1074_CR35","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","volume":"396","author":"R Savarirayan","year":"2020","unstructured":"Savarirayan, R. et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet 396, 684\u2013692 (2020).","journal-title":"Lancet"},{"key":"1074_CR36","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","volume":"23","author":"R Savarirayan","year":"2021","unstructured":"Savarirayan, R. et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase 3 extension study. Genet. Med. 23, 2443\u20132447 (2021).","journal-title":"Genet. Med."},{"key":"1074_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S2352-4642(23)00265-1","volume":"8","author":"R Savarirayan","year":"2024","unstructured":"Savarirayan, R. et al. Vosoritide therapy in children with achondroplasia aged 3-59 months: a multinational, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Child. Adolesc. Health 8, 40\u201350 (2024).","journal-title":"Lancet Child. Adolesc. Health"},{"key":"1074_CR38","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40262-021-01059-1","volume":"61","author":"ML Chan","year":"2022","unstructured":"Chan, M. L. et al. Pharmacokinetics and exposure-response of vosoritide in children with achondroplasia. Clin. Pharmacokinet. 61, 263\u2013280 (2022).","journal-title":"Clin. Pharmacokinet."},{"issue":"1 Suppl.","key":"1074_CR39","first-page":"55","volume":"1","author":"J Hoover-Fong","year":"2023","unstructured":"Hoover-Fong, J. et al. Persistent growth-promoting effects of vosoritide in children with achondroplasia for up to 3.5 years: update from phase 3 extension study [abstract P193]. GIM Open 1(1 Suppl.), 55 (2023).","journal-title":"GIM Open"},{"key":"1074_CR40","unstructured":"Pharmaceuticals and Medical Devices Agency. New drugs approved in FY 2022. Japanese Regulatory Authority www.pmda.go.jp\/files\/000267877.pdf (2022)."},{"key":"1074_CR41","unstructured":"Australian Government Department of Health and Aged Care. Voxzogo. Therapeutic Goods Administration www.tga.gov.au\/resources\/auspmd\/voxzogo#:~:text=Voxzogo%20(vosoritide)%20was%20approved%20for,confirmed%20by%20appropriate%20genetic%20testing (2022)."},{"key":"1074_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01971-6","volume":"16","author":"V Cormier-Daire","year":"2021","unstructured":"Cormier-Daire, V. et al. The first European consensus on principles of management for achondroplasia. Orphanet J. Rare Dis. 16, 333 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1074_CR43","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2020-1010","volume":"145","author":"J Hoover-Fong","year":"2020","unstructured":"Hoover-Fong, J., Scott, C. I. & Jones, M. C. Health supervision for people with achondroplasia. Pediatrics 145, e20201010 (2020).","journal-title":"Pediatrics"},{"key":"1074_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1297\/cpe.29.25","volume":"29","author":"T Kubota","year":"2020","unstructured":"Kubota, T. et al. Clinical practice guidelines for achondroplasia. Clin. Pediatr. Endocrinol. 29, 25\u201342 (2020).","journal-title":"Clin. Pediatr. Endocrinol."},{"key":"1074_CR45","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s12887-022-03505-w","volume":"22","author":"J Llerena Jr.","year":"2022","unstructured":"Llerena, J. Jr. et al. Achondroplasia in Latin America: practical recommendations for the multidisciplinary care of pediatric patients. BMC Pediatr. 22, 492 (2022).","journal-title":"BMC Pediatr."},{"key":"1074_CR46","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41574-021-00595-x","volume":"18","author":"R Savarirayan","year":"2022","unstructured":"Savarirayan, R. et al. International Consensus Statement on the diagnosis, multidisciplinary management and lifelong care of individuals with achondroplasia. Nat. Rev. Endocrinol. 18, 173\u2013189 (2022).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1074_CR47","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/jpc.16290","volume":"59","author":"LJ Tofts","year":"2023","unstructured":"Tofts, L. J. et al. Australian guidelines for the management of children with achondroplasia. J. Paediatr. Child. Health 59, 229\u2013241 (2023).","journal-title":"J. Paediatr. Child. Health"},{"key":"1074_CR48","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s12325-023-02705-9","volume":"41","author":"O Semler","year":"2024","unstructured":"Semler, O. et al. Vosoritide therapy in children with achondroplasia: early experience and practical considerations for clinical practice. Adv. Ther. 41, 198\u2013214 (2024).","journal-title":"Adv. Ther."},{"key":"1074_CR49","doi-asserted-by":"publisher","first-page":"789","DOI":"10.3390\/children11070789","volume":"11","author":"L Tofts","year":"2024","unstructured":"Tofts, L. et al. Consensus guidelines for the use of vosoritide in children with achondroplasia in Australia. Children 11, 789 (2024).","journal-title":"Children"},{"key":"1074_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01813-5","volume":"16","author":"SE Mole","year":"2021","unstructured":"Mole, S. E. et al. Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients. Orphanet J. Rare Dis. 16, 185 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1074_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02372-z","volume":"17","author":"R Savarirayan","year":"2022","unstructured":"Savarirayan, R. et al. Literature review and expert opinion on the impact of achondroplasia on medical complications and health-related quality of life and expectations for long-term impact of vosoritide: a modified Delphi study. Orphanet J. Rare Dis. 17, 224 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"1074_CR52","doi-asserted-by":"publisher","first-page":"368504211003782","DOI":"10.1177\/00368504211003782","volume":"104","author":"R Savarirayan","year":"2021","unstructured":"Savarirayan, R. et al. Rationale, design, and methods of a randomized, controlled, open-label clinical trial with open-label extension to investigate the safety of vosoritide in infants, and young children with achondroplasia at risk of requiring cervicomedullary decompression surgery. Sci. Prog. 104, 368504211003782 (2021).","journal-title":"Sci. Prog."},{"key":"1074_CR53","unstructured":"American Academy of Pediatrics. Shared decision making. American Academy of Pediatrics www.aap.org\/en\/practice-management\/providing-patient--and-family-centered-care\/shared-decision-making\/ (2021)."},{"key":"1074_CR54","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s12325-023-02496-z","volume":"40","author":"S NiMhurchadha","year":"2023","unstructured":"NiMhurchadha, S. et al. Parents\u2019 experience of administering vosoritide: a daily injectable for children with achondroplasia. Adv. Ther. 40, 2457\u20132470 (2023).","journal-title":"Adv. Ther."},{"issue":"2 Suppl. 1","key":"1074_CR55","first-page":"9","volume":"2","author":"R Savarirayan","year":"2024","unstructured":"Savarirayan, R. et al. Persistent growth-promoting effects of vosoritide in children with achondroplasia is accompanied by improvement in physical aspects of quality of life [abstract P141]. GIM Open 2(2 Suppl. 1), 9 (2024).","journal-title":"GIM Open"},{"key":"1074_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01681-z","volume":"16","author":"PJ Ireland","year":"2021","unstructured":"Ireland, P. J. et al. Development of the Screening Tool for Everyday Mobility and Symptoms (STEMS) for skeletal dysplasia. Orphanet J. Rare Dis. 16, 40 (2021).","journal-title":"Orphanet J. Rare Dis."},{"key":"1074_CR57","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0003-9993(95)80066-2","volume":"76","author":"NL Young","year":"1995","unstructured":"Young, N. L., Yoshida, K. K., Williams, J. I., Bombardier, C. & Wright, J. G. The role of children in reporting their physical disability. Arch. Phys. Med. Rehabil. 76, 913\u2013918 (1995).","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"1074_CR58","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke, K., Spitzer, R. L. & Williams, J. B. The PHQ-9: validity of a brief depression severity measure. J. Gen. Intern. Med. 16, 606\u2013613 (2001).","journal-title":"J. Gen. Intern. Med."},{"key":"1074_CR59","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/00005650-199902000-00003","volume":"37","author":"JW Varni","year":"1999","unstructured":"Varni, J. W., Seid, M. & Rode, C. A. The PedsQL: measurement model for the pediatric quality of life inventory. Med. Care 37, 126\u2013139 (1999).","journal-title":"Med. Care"},{"key":"1074_CR60","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1080\/09638288.2016.1226969","volume":"39","author":"R Sommer","year":"2017","unstructured":"Sommer, R. et al. An ICF-CY-based approach to assessing self- and observer-reported functioning in young persons with achondroplasia \u2013 development of the pilot version of the Achondroplasia Personal Life Experience Scale (APLES). Disabil. Rehabil. 39, 2499\u20132503 (2017).","journal-title":"Disabil. Rehabil."},{"key":"1074_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02755-w","volume":"18","author":"Y Alanay","year":"2023","unstructured":"Alanay, Y. et al. Real-world evidence in achondroplasia: considerations for a standardized data set. Orphanet J. Rare Dis. 18, 166 (2023).","journal-title":"Orphanet J. Rare Dis."},{"key":"1074_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02479-3","volume":"17","author":"S Fredwall","year":"2022","unstructured":"Fredwall, S. et al. Optimising care and follow-up of adults with achondroplasia. Orphanet J. Rare Dis. 17, 318 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"1074_CR63","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1007\/s12325-024-02880-3","volume":"41","author":"S Fredwall","year":"2024","unstructured":"Fredwall, S. et al. European Achondroplasia Forum practical considerations for following adults with achondroplasia. Adv. Ther. 41, 2545\u20132558 (2024).","journal-title":"Adv. Ther."},{"key":"1074_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-02142-3","volume":"17","author":"V Fano","year":"2022","unstructured":"Fano, V. et al. Impact of achondroplasia on Latin American patients: a systematic review and meta-analysis of observational studies. Orphanet J. Rare Dis. 17, 4 (2022).","journal-title":"Orphanet J. Rare Dis."},{"key":"1074_CR65","doi-asserted-by":"publisher","first-page":"116472","DOI":"10.1016\/j.bone.2022.116472","volume":"162","author":"M Stender","year":"2022","unstructured":"Stender, M., Pimenta, J. M., Cheung, M., Irving, M. & Mukherjee, S. Comprehensive literature review on the prevalence of comorbid conditions in patients with achondroplasia. Bone 162, 116472 (2022).","journal-title":"Bone"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01074-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:11:21Z","timestamp":1746177081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01074-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,6]]},"references-count":65,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1074"],"URL":"https:\/\/doi.org\/10.1038\/s41574-024-01074-9","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,6]]},"assertion":[{"value":"28 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BioMarin provided financial support for this project. In addition to the individual competing interests outlined below, all authors declare travel to the meeting and accommodation reimbursement, and honorarium payments for meeting participation and Delphi voting (on which this manuscript is based) from BioMarin Pharmaceutical Inc. R.S. reported receiving consulting fees and grants from BioMarin, participation on advisory boards with Ascendis and BioMarin, and consulting for BridgeBio. J.H.-F. reported grants or contracts for clinical trials from BioMarin, QED and Pfizer, consulting fees from BioMarin, QED, NovoNordisk and Innoskel, honoraria from Medscape and BioMarin, participation in Advisory Board meetings for MCDS-Therapy Clinical Trial (unpaid), BioMarin and QED. K. Ozono reported receiving honoraria from Alexion, Kyowa Kirin, and BioMarin. P.B. reported participating on a data monitoring committee and receiving consulting fees and honoraria from BioMarin. V.C.-D. reported payment or honoraria for lectures\/presentations from BioMarin and Ipsen, and participation in Advisory Board meetings for BioMarin, QED-Propel and Mereo. K.DeA. reported participating on advisory boards for BioMarin and BridgeBio and attending meetings with BioMarin, BridgeBio, Ascendis, and Tyra Biosciences. P.I. reported honoraria and support for attending meetings from BioMarin and a start-up grant to her institution from BioMarin. M.I. reported honoraria for consultancy services from BioMarin, QED Therapeutics, Pfizer\/Therachon, Sanofi, Ascendis, Alexionk, Kyowa Kirin, Innoskel and NovoNordisk. J.L.J. reported participation on a data safety monitoring board\/advisory board, receiving consulting fees and honoraria from BioMarin and Sanofi. M. Maghnie reported participating on a data safety monitoring\/advisory board and receiving consulting fees and honoraria from Pfizer, Novo Nordisk, Merck, Sandoz and BioMarin. N.M. reported receiving consulting fees from Pfizer, BioMarin and Alexion, and honoraria from Medscape, Springer, Science Collected and TouchIM. N.M. also reported receiving support for attending meetings from Parent Project of Muscular Dystrophy and PESTOLA and holds a leadership or fiduciary role in the Board of Positive Exposure and the ACMG DEI committee. K.M. reported grants or contracts for clinical trials, honoraria and support for attending meetings, and has participated in Advisory Board meetings for BioMarin. K. Okada reported payment or honoraria for lectures\/presentations from BioMarin and Alexion, and participation in advisory board meetings for BioMarin. S.N.I., M. Menzel and S.O.F. declare no additional competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}